These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 10665628)
1. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Feighner JP; Overø K J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628 [TBL] [Abstract][Full Text] [Related]
2. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Burke WJ; Gergel I; Bose A J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207 [TBL] [Abstract][Full Text] [Related]
3. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239 [TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Mendels J; Kiev A; Fabre LF Depress Anxiety; 1999; 9(2):54-60. PubMed ID: 10207659 [TBL] [Abstract][Full Text] [Related]
6. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Azorin JM; Llorca PM; Despiegel N; Verpillat P Encephale; 2004; 30(2):158-66. PubMed ID: 15107719 [TBL] [Abstract][Full Text] [Related]
7. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. Thase ME J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690 [TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. Mehtonen OP; Søgaard J; Roponen P; Behnke K J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656 [TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Bielski RJ; Ventura D; Chang CC J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045 [TBL] [Abstract][Full Text] [Related]
11. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner CM; Brown EB; Gonzales JS; Munir R J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723 [TBL] [Abstract][Full Text] [Related]
13. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623 [TBL] [Abstract][Full Text] [Related]
14. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. Feighner J; Targum SD; Bennett ME; Roberts DL; Kensler TT; D'Amico MF; Hardy SA J Clin Psychiatry; 1998 May; 59(5):246-53. PubMed ID: 9632036 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Kyle CJ; Petersen HE; Overø KF Depress Anxiety; 1998; 8(4):147-53. PubMed ID: 9871816 [TBL] [Abstract][Full Text] [Related]
17. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. Wheatley DP; van Moffaert M; Timmerman L; Kremer CM J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343 [TBL] [Abstract][Full Text] [Related]
18. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291 [TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Stahl SM Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227 [TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Lydiard RB; Stahl SM; Hertzman M; Harrison WM J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]